Dapagliflozin Reduces New-Onset T2D in Patients With CKD, HF Dapagliflozin Reduces New-Onset T2D in Patients With CKD, HF

In patients with chronic kidney disease and heart failure, dapagliflozin curbed the incidence of new-onset type 2 diabetes without reducing HbA1c in a pooled analysis of the DAPA-CKD and DAPA-HF trials.Reuters Health Information
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Diabetes & Endocrinology News Source Type: news